From candidate to default: the company has just been placed inside buyers' own purchasing systems
The model's full reasoning — Q4 2021 call → NO我们根据提供的财报电话会议记录来判断。管理层是否描述了公司最近从需要说服的候选者转变为已批准、指定、列入、合格、注册、报销或预先授权的选择,从而进入买方的采购、报销、处方集、规格、采购、网络、目录或计划系统,使得未来业务的一部分可以无需每次单独销售事件就能到来,并且管理层是否传达这种准入状态是新的,以至于它解锁的大部分量仍在前方? 在记录中,管理层讨论了AMP-100的PDUFA日期(2022年10月),并计划在批准后推出。他们提到“如果获得批准,我们打算在几个月后推出AMP-100”,并讨论了对该产品的兴奋。然而,他们明确表示产品尚未获得批准,批准是未来的事件。他们提到“我们确实认为我们很有可能获得产品批准”,但这是条件性的。他们没有描述公司已被列入任何处方集、供应商名单或报销路径。他们提到“申请通过状态”(pass-through status),但这是申请,不是已获得。他们提到“我们打算申请通过状态”,所以这是未来的申请。 关于现有业务,他们描述了持续增长和客户关系,但没有提到任何新的准入状态。他们提到“我们正在扩大现有的商业基础设施”,但这是关于销售团队,不是关于系统准入。 因此,管理层没有描述公司已进入任何买方系统。所有关于AMP-100的讨论都是关于未来批准和推出,尚未发生。所以答案应为NO。
| Ticker | Company | Call | Date | Call grade |
|---|---|---|---|---|
| WRBY | Warby Parker Inc. | Q1 2024 | 2024-05-09 | A |
| AZEK | The AZEK Company Inc. | Q2 2024 | 2024-05-08 | B+ |
| DXCM | DexCom, Inc. | Q4 2023 | 2024-02-08 | B+ |
| SCPH | scPharmaceuticals Inc. | Q3 2023 | 2023-11-08 | B |
| INGN | Inogen, Inc. | Q1 2023 | 2023-05-05 | F |
| HBB | Hamilton Beach Brands Holding Company | Q3 2022 | 2022-11-05 | C |
| EVGO | EVgo, Inc. | Q2 2022 | 2022-08-09 | C+ |
| OPK | OPKO Health, Inc. | Q1 2022 | 2022-05-09 | D |
| MGNI | Magnite, Inc. | Q1 2022 | 2022-05-04 | D |
| AGIO | Agios Pharmaceuticals, Inc. | Q3 2018 | 2018-11-01 | C |
| PRIM | Primoris Services Corporation | Q2 2018 | 2018-08-11 | C+ |
| IONS | Ionis Pharmaceuticals, Inc. | Q1 2017 | 2017-05-09 | C |
PRIM · Q2 2018 → YESThe question is about whether management describes that the company has recently crossed from being a candidate that buyers must be persuaded to consider into being an approved, specified, listed, qua...YES The transcript shows management describing exactly this shift for the newly acquired T&D segment: after the Willbros acquisition (closed June 1, 2018), the T&D Group gained access to major utilities that had been hesitant due to prior financial concerns. With Primoris as parent, they signed new awards from the 3 largest electrical utilities (one announced MSA, two not yet announced), allowing work to flow under existing relationships without repeated persuasion. Management explicitly ties this to the recent acquisition and notes the MSA backlog now at $1.1 billion (first time exceeding $1 billion), with one-year estimated MSA revenue at $1.1 billion and continued growth expected.
AGIO · Q3 2018 → YESThe question is about whether management describes that the company has recently crossed from being a candidate that buyers must be persuaded to consider into being an approved, specified, listed, qua...YES The transcript shows management describing exactly this transition for TIBSOVO. Steve Hoerter states that the company launched in July 2018 and is now receiving reimbursement with “no payer-related coverage issues,” with the payer mix (60% Medicare, 35% commercial) reflecting routine placement in those systems. He further notes that initial prescriptions are being written by over 100 unique prescribers and that awareness is already above 90%, confirming the product has moved from candidate status into the reimbursement and purchasing pathways. Because the launch is only a few months old at the time of the call, the $4.
AZEK · Q2 2024 → YESThe question is about whether management describes that the company has recently crossed from being a candidate that buyers must be persuaded to consider into being an approved, specified, listed, etc...YES The transcript shows management describing recent and incremental shelf-space gains in both pro and retail channels as a new development that will support growth in 2025, with investments planned for Q4 to enable these gains. This is framed as moving beyond prior years' steady execution into fresh wins that create a tailwind for future 2025 volume, where the company is now positioned to benefit from expanded availability in buyer systems (catalogs, dealer networks, and retail displays) without needing to re-persuade for each order.